
Figure 1.
PRISMA 2020 Flow Diagram of the Identification, Screening, Eligibility Assessment, and Inclusion of Evidence Sources on the Neuropsychiatric Safety of GLP-1 Receptor Agonists and Tirzepatide.

Figure 1.
PRISMA 2020 Flow Diagram of the Identification, Screening, Eligibility Assessment, and Inclusion of Evidence Sources on the Neuropsychiatric Safety of GLP-1 Receptor Agonists and Tirzepatide.